Stay updated on STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedClinicalTrials.gov’s page revision/version updated from **v3.5.2** to **v3.5.3**, indicating a site release rather than a change to the study information.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0; there are no visible edits to the study details content.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check75 days agoChange DetectedFallopian tube cancer was added to the conditions list. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded primary peritoneal carcinoma to the conditions and included the Genetic and Rare Diseases Information Center under resources. Revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

Stay in the know with updates to STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.